Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study-Reference-Cited by-同舟云学术

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

Published:2007-10-09 Issue:3 Volume:62 Page:393-400
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Koensgen Dominique,Stengel Dirk,Belau Antje,Klare Peter,Oskay-Oezcelik Guelten,Steck Thomas,Camara Oumar,Mustea Alexander,Sommer Harald,Coumbos Alexandra,Bogenrieder Thomas,Lichtenegger Werner,Sehouli Jalid,

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-007-0617-2.pdf

Reference32 articles.

1. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130

2. Ozols RF, Bookman MA, Connolly DC et al (2004) Focus on epithelial ovarian cancer. Cancer Cell 5:19–24

3. Markmann M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393

4. Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207–211

5. Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375):2099–2106

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment;Molecular Cancer Therapeutics;2023-09-08

2. Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review;Gynecologic Oncology;2019-02

3. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR);Annals of Oncology;2016-12

4. Major clinical research advances in gynecologic cancer in 2012;Journal of Gynecologic Oncology;2013

5. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial;Journal of Cancer Research and Clinical Oncology;2012-11-18